Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases

Launched by UNIVERSITY HOSPITAL, TOULOUSE · Mar 31, 2022

Keywords

ClinConnect Summary

This clinical trial, called Nephrogene 2.0, is looking at how certain biological factors can help us understand and manage kidney diseases, including acute kidney injury and chronic kidney diseases, as well as issues related to organ transplants and immune system disorders. The goal is to learn more about what causes these conditions, how they might get worse, and how to predict complications, so that doctors can provide better care for patients.

To participate in this study, you need to be over 18 years old and either have kidney disease or be at risk of developing it. You must also be under the care of a doctor at the Department of Nephrology and Organ Transplantations at the University Hospital of Toulouse in France. If you join the trial, you can expect to undergo some tests and assessments that will help researchers gather important information about your health. It’s important to note that if you or your family cannot give consent, you won’t be able to participate. This trial is currently recruiting participants, so there is an opportunity to contribute to important research that could improve kidney care for many people.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients (\> 18 year of age) with kidney disease or at risk to develop a kidney disease,
• • Patients followed by a practitioner of the Department of Nephrology and Organ Transplantations of the University Hospital of Toulouse (France)
• Exclusion Criteria:
• • consent deny
• • inability of the patient or its family to give consent.